Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a few claims can be verified as supported by the provided label excerpts (e.g., topical-only use, indications for facial acne vulgaris mild-to-moderate and plaque psoriasis up to 20% BSA, pregnancy contraindication, and local irritation including burning/erythema). Most efficacy/statistics, comparative effectiveness, dosing details (dose size/frequency/titration), photosensitivity counseling phrasing, and specific pregnancy-label wording (“category X”) are unsupported or not evidenced in the supplied label text.
Category Scores
Accurate Statements
Tazarotene is a topical retinoid.
Label context indicates Trilitas™ (tazarotene) gel is for topical use only; tazarotene is a retinoid class implied by label naming ('topical tazarotene').
Tazarotene is FDA-approved for acne vulgaris.
Indications and Usage (1): indicated for facial acne vulgaris of mild to moderate severity.
For psoriasis, tazarotene leads to plaque clearance in plaque psoriasis.
Clinical Studies (14) are referenced in label assessment as containing plaque psoriasis efficacy data; exact phrasing 'plaque clearance' not directly quoted in provided excerpts but is consistent with plaque psoriasis topical treatment indicated.
Tazarotene is contraindicated in pregnancy due to fetal risks from retinoid teratogenicity.
Contraindications (4): 'Pregnancy. Retinoids may cause fetal harm…'; Use in Specific Populations (8.1): contraindicated during pregnancy and 'may cause fetal harm.'
Common side effects of tazarotene include burning.
Warnings and Precautions (5.2): local reactions include 'burning'.
Common side effects of tazarotene include redness.
Warnings and Precautions (5.2): local reactions include 'erythema'.
Common side effects of tazarotene include peeling.
Warnings and Precautions (5.2): local reactions include 'skin desquamation'.
Common side effects of tazarotene include dryness.
Not explicitly supported by the provided excerpts. (Local irritation and desquamation are mentioned, but 'dryness' is not stated verbatim in the supplied text.)
Unsupported Statements
Tazarotene reduces acne lesions by normalizing skin cell turnover.
No mechanism statement about acne 'normalizing skin cell turnover' in provided label excerpts.
Tazarotene reduces acne lesions by unclogging pores.
No pore/unclogging mechanism in provided label excerpts.
Tazarotene reduces acne lesions by decreasing inflammation.
No acne mechanism about decreasing inflammation in provided label excerpts.
In clinical trials, tazarotene cuts inflammatory and non-inflammatory acne by 50-70% after 12 weeks at 0.1% strength.
No specific percentage or '50-70% after 12 weeks' efficacy values are present in the provided label excerpts.
In those clinical trials, tazarotene outperformed vehicle controls (p<0.01).
No p-value (p<0.01) or vehicle-control statistical result shown in the provided excerpts.
A meta-analysis of 24 studies found moderate-to-severe acne improvement in 60-80% of patients treated with tazarotene.
Meta-analysis claim not supported by provided label excerpts.
The best results for acne with tazarotene occurred when combined with benzoyl peroxide.
No combination therapy comparative effectiveness statement in provided excerpts.
The best results for acne with tazarotene occurred when combined with antibiotics.
No such combination-best-efficacy claim supported by provided excerpts.
For psoriasis, tazarotene inhibits keratinocyte proliferation.
No psoriasis mechanism statement about keratinocyte proliferation in provided excerpts.
For psoriasis, tazarotene modulates inflammation.
No psoriasis mechanism statement about inflammation modulation in provided excerpts.
In pivotal trials, 20-40% of patients achieved near-complete clearing (≥90% improvement) with tazarotene after 12 weeks.
No numeric '20-40%' or '≥90% improvement' results provided in excerpts.
In those pivotal trials, 10% of patients achieved near-complete clearing (≥90% improvement) with placebo after 12 weeks.
No numeric placebo comparator results provided in excerpts.
Tazarotene is more effective on thin plaques than thick ones.
No stratified efficacy by plaque thickness in provided excerpts.
Tazarotene works faster than calcipotriene alone.
No comparative efficacy vs calcipotriene timing statement in provided excerpts.
Tazarotene irritation limits adherence.
No adherence-related counseling/statement in provided excerpts.
Tazarotene is FDA-approved for mild-to-moderate plaque psoriasis.
Label excerpt indicates plaque psoriasis of up to 20% body surface area involvement; does not state 'mild-to-moderate plaque psoriasis.'
In head-to-head comparison for acne vs. adapalene 0.1%, tazarotene has similar lesion reduction.
No head-to-head adapalene comparative statement in provided excerpts.
In that head-to-head comparison, tazarotene is faster on inflammatory acne than adapalene 0.1%.
No comparative 'faster' statement in provided excerpts.
In head-to-head comparison for acne vs. tretinoin, tazarotene is superior for comedones.
No head-to-head tretinoin/comedo superiority statement in provided excerpts.
In that head-to-head comparison, comedone clearance was 55% with tazarotene vs. 40% with tretinoin.
No numeric comedone clearance comparison in provided excerpts.
In head-to-head comparison for psoriasis vs. calcipotriene, combination therapy clears 50-70% more plaques than monotherapy.
No such comparative combination therapy efficacy data in provided excerpts.
In head-to-head comparison for psoriasis vs. betamethasone, tazarotene has equal efficacy.
No head-to-head vs betamethasone efficacy equivalence in provided excerpts.
Compared with betamethasone, tazarotene avoids steroid atrophy.
No statement comparing steroid atrophy in provided excerpts.
Common side effects of tazarotene include dryness.
Provided excerpts mention burning/erythema/desquamation but do not mention 'dryness' specifically.
Burning, redness, peeling, and dryness affect 10-30% of users of tazarotene.
No incidence range (10-30%) in provided excerpts.
Those side effects peak in weeks 2-4.
No time-to-peak (weeks 2-4) statement in provided excerpts.
Those side effects ease with moisturizers or lower dosing.
The excerpts provided do not include moisturizer/lower dosing guidance or timing specifics (they do allude to advice on discontinuing/reducing frequency but no 'moisturizers' statement is included in provided text).
Tazarotene has pregnancy category X.
No 'Pregnancy Category X' labeling is present in provided excerpts.
Tazarotene is not ideal for sensitive skin.
While the label warns about 'excessive irritation in certain sensitive individuals,' the specific wording 'not ideal for sensitive skin' is not verbatim and is not clearly supported as a standalone recommendation.
Tazarotene is not ideal for severe cases needing systemic therapy.
No statement about systemic therapy needs or suitability in severe cases in provided excerpts.
Tazarotene is applied as a pea-sized amount once nightly to clean, dry skin.
Label dosing specifies 2 mg/cm^2 thin film and 'once per day, in the evening' after skin is dry; 'pea-sized amount' is not in provided excerpts.
Treament may be started every other night to build tolerance.
No 'every other night' titration schedule in provided excerpts.
Using sunscreen is stated as mandatory because it increases photosensitivity.
Provided excerpt states avoiding sunlight/sunlamps and minimizing exposure; it does not say 'sunscreen is mandatory' nor claim that sunscreen 'increases photosensitivity.'
A 12-week course of tazarotene is typical for acne.
No '12-week course is typical' statement in provided excerpts.
For psoriasis, tazarotene is stated to be safe up to 12 months with breaks.
No 'safe up to 12 months with breaks' statement in provided excerpts.
Contradictions
Important Omissions
Accurate, label-specific dosing quantity/dose surface area for each indication (2 mg/cm^2 thin film; cover only psoriatic lesions on no more than 20% BSA for psoriasis).
Importance:
Moderate
Topical-only administration safety instructions (not ophthalmic/oral/intravaginal; avoid contact with mucous membranes; rinse if contact occurs; wash hands after application).
Importance:
Moderate
Photosensitivity precaution should be framed as sunlight avoidance/minimization rather than 'sunscreen mandatory' (the provided label excerpt emphasizes avoiding exposure).
Importance:
Moderate
For acne, the indication is specifically 'facial acne vulgaris of mild to moderate severity' and the label states efficacy in certain resistant/acne previously treated with other retinoids is not established.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several dosing, duration, and administration details are unsupported (e.g., 'pea-sized amount,' 'every other night,' '12-week typical course,' '12 months safe with breaks') and could lead to inaccurate use. Multiple efficacy/statistical claims are unsupported. Misframing photosensitivity counseling ('sunscreen mandatory because it increases photosensitivity') may misguide risk mitigation relative to label language.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portion of claims (efficacy percentages/p-values, comparative effectiveness, mechanistic explanations, dosing/titration/duration, and specific counseling assertions) are not supported by the provided FDA label excerpts; some details may conflict with label-specific wording (e.g., psoriasis 'mild-to-moderate' vs 'up to 20% BSA'; photosensitivity guidance phrasing; 'pregnancy category X').
Suggested Improvement
Limit claims to the provided label-supported text: indications (facial acne mild-to-moderate; plaque psoriasis up to 20% BSA), label dosing method (2 mg/cm^2 thin film; once daily in evening; psoriasis lesion coverage limits), topical-only restrictions (avoid eyes/mouth/mucous membranes; rinse if contact occurs; wash hands), contraindication in pregnancy, and label-listed local irritation reactions (burning/erythema/desquamation). Remove unsupported numeric efficacy, comparative claims, and unquoted counseling specifics.